Taibi Mohamed, Elbouzidi Amine, Haddou Mounir, Baraich Abdellah, Ou-Yahia Douaae, Bellaouchi Reda, Mothana Ramzi A, Al-Yousef Hanan M, Asehraou Abdeslam, Addi Mohamed, Guerrouj Bouchra El, Chaabane Khalid
Laboratoire d'Amélioration des Productions Agricoles, Biotechnologie et Environnement (LAPABE), Faculté des Sciences, Université Mohammed Premier, Oujda 60000, Morocco.
Centre de l'Oriental des Sciences et Technologies de l'Eau et de l'Environnement (COSTEE), Université Mohammed Premier, Oujda 60000, Morocco.
Life (Basel). 2024 Aug 20;14(8):1037. doi: 10.3390/life14081037.
The objective of this study was to evaluate the antioxidant, anti-inflammatory, and anticancer properties of thymol, carvacrol, and their equimolar mixture. Antioxidant activities were assessed using the DPPH, ABTS, and ORAC methods. The thymol/carvacrol mixture exhibited significant synergism, surpassing the individual compounds and ascorbic acid in DPPH (IC = 43.82 ± 2.41 µg/mL) and ABTS (IC = 23.29 ± 0.71 µg/mL) assays. Anti-inflammatory activity was evaluated by inhibiting the 5-LOX, COX-1, and COX-2 enzymes. The equimolar mixture showed the strongest inhibition of 5-LOX (IC = 8.46 ± 0.92 µg/mL) and substantial inhibition of COX-1 (IC = 15.23 ± 2.34 µg/mL) and COX-2 (IC50 = 14.53 ± 2.42 µg/mL), indicating a synergistic effect. Anticancer activity was tested on MCF-7, MDA-MB-231, and MDA-MB-436 breast cancer cell lines using the MTT assay. The thymol/carvacrol mixture demonstrated superior cytotoxicity (IC = 0.92-1.70 µg/mL) and increased selectivity compared to cisplatin, with high selectivity indices (144.88-267.71). These results underscore the promising therapeutic potential of the thymol/carvacrol combination, particularly for its synergistic antioxidant, anti-inflammatory, and anticancer properties against breast cancer. This study paves the way for developing natural therapies against breast cancer and other conditions associated with oxidative stress and inflammation, leveraging the synergistic effects of natural compounds like thymol and carvacrol.
本研究的目的是评估百里香酚、香芹酚及其等摩尔混合物的抗氧化、抗炎和抗癌特性。使用DPPH、ABTS和ORAC方法评估抗氧化活性。在DPPH（IC = 43.82 ± 2.41 µg/mL）和ABTS（IC = 23.29 ± 0.71 µg/mL）测定中，百里香酚/香芹酚混合物表现出显著的协同作用，超过了单一化合物和抗坏血酸。通过抑制5-LOX、COX-1和COX-2酶来评估抗炎活性。等摩尔混合物对5-LOX表现出最强的抑制作用（IC = 8.46 ± 0.92 µg/mL），对COX-1（IC = 15.23 ± 2.34 µg/mL）和COX-2（IC50 = 14.53 ± 2.42 µg/mL）有显著抑制作用，表明存在协同效应。使用MTT法在MCF-7、MDA-MB-231和MDA-MB-436乳腺癌细胞系上测试抗癌活性。与顺铂相比，百里香酚/香芹酚混合物表现出更高的细胞毒性（IC = 0.92 - 1.70 µg/mL）和更高的选择性，具有高选择性指数（144.88 - 267.71）。这些结果强调了百里香酚/香芹酚组合具有广阔的治疗潜力，特别是其对乳腺癌的协同抗氧化、抗炎和抗癌特性。本研究为开发针对乳腺癌和其他与氧化应激和炎症相关疾病的天然疗法铺平了道路，利用了百里香酚和香芹酚等天然化合物的协同效应。
